All of these factors may result in the differential contribution of TRPM7 to the pathogenesis in PAH and therefore the therapeutic efficacy of its inhibition may be limited to certain types and stages of PAH. This evidence concerns the gene TRPM7 and pulmonary arterial hypertension.